15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
ANALYST CONSENSUS0 ratings
No Rating
Strong Buy00%
Buy00%
Hold00%
Sell00%
Strong Sell00%
Analyst rating coverage is not available for BCAB yet.
12-MONTH PRICE TARGET
—
Average analyst target vs $3.33 current
Highest Target—
Average Target—
Lowest Target—
BCAB analyst recommendation trends
86420
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Strong BuyBuyHoldSellStrong Sell
RATING
FEB
MAR
APR
MAY
JUN
JUL
Strong Buy
0
0
0
0
0
0
Buy
1
0
0
0
0
0
Hold
2
1
1
1
1
1
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
3
1
1
1
1
1
As of Jul, 0 of 1 firms rate BCAB a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BCAB EPS & revenue forecast
EPS · THIS QUARTER
$-0.24
Range $-0.24 – $-0.24 · 1 analysts · -20% YoY
Next period, 1 analysts expect Bioatla Inc to earn $-0.24 a share (range $-0.24 – $-0.24), versus $-0.30 a year earlier.
REVENUE · THIS QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —)., rising to $0 next year.
Top analysts covering Bioatla Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BCAB.
#1
Arthur He
HC Wainwright & Co. · Rank #155
Hold
No targeton BCAB
Overall win rate
50%
+ Follow
#2
Reni J. Benjamin
JMP Securities · Rank #353
Hold
No targeton BCAB
Overall win rate
33%
+ Follow
#3
MK
Michael King
Rodman & Renshaw
Buy
$200.00+5906.0% to target
Coverage
—
+ Follow
#4
Justin Zelin
BTIG
Buy
$500.00+14915.0% to target
Coverage
—
+ Follow
#5
AH
Arthur He CFA
H.C. Wainwright
Hold
No targeton BCAB
Coverage
—
+ Follow
BCAB stock forecast FAQ
Who is the most accurate analyst covering BCAB?+
Among analysts who currently cover BCAB, Arthur He of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #155). Their current call is Hold.
What is Bioatla Inc's projected EPS for next quarter?+
The consensus estimate is $-0.24 per share (range $-0.24 – $-0.24) across 1 analysts, rising to — the following year.
How much revenue is Bioatla Inc expected to report next quarter?+
Consensus revenue is — (range — – —), growing to $0 next year.
Have analysts been upgrading or downgrading BCAB lately?+
As of Jul, 0 of 1 firms rate BCAB a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BCAB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
